Oscar Health, Inc. Stock Prediction and Forecast [OSCR]

AI-generated source summary

The Oscar Health, Inc. stock is currently classified as a strong sell candidate, reflecting a score of -4.125 since October 23, 2025. This period has seen a cumulative loss of 25.58%, averaging a daily decline of 1.97%. On November 10, 2025, the stock closed at $14.60, marking a 17.60% drop from its opening. Over the last 10 trading days, the price has decreased in nine sessions, contributing to a 25.77% reduction in value. Trading volume increased by 24 million shares on the last day, accompanying falling prices, which is identified as an early warning of increased risk. Fundamental analysis reveals a negative P/E ratio of -15.29, indicating unprofitability. Q3 revenue fell short of estimates at $3.0 billion, and the company reported a wider loss. While management projects a return to profitability in 2026, near-term margins are constrained by rising costs. Analyst ratings are predominantly neutral to underweight, with a general rating of D+ (strong sell). Technically, short and long-term Moving Averages, MACD, and pivots display sell signals, with identified resistance levels at $16.96 and $19.28. No significant support from accumulated volume is found below current levels, suggesting potential for further sharp declines. The stock exhibits high weekly volatility at 9.75% and is classified as high risk. Given these negative indicators, a weak performance is anticipated in the coming days or weeks, despite some ambiguous longer-term trend projections. The open price for November 11 is expected to be $15.11, opening higher by approximately $0.509.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   11 Nov 2025, 04:50 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   02 Jul 2026, 02:13 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. First prediction resolved

   02 Jul 2026, 02:13 UTC

   The first evaluable outcome in this case reached a terminal result.

6. Case evaluation completed

   02 Jul 2026, 02:13 UTC

   All evaluable predictions in this case reached terminal outcomes.